Investigative and Preclinical Toxicology Summit 2026

Memo

Benchmark Existing Models and Interrogate Practical Applications of NAMs to Accelerate More Predictive In Vitro, In Vivo, and Computational ModelsWith nearly 90% of drug candidates failing in the clinic, and one-third of those failures driven by safety, toxicology has reached a critical inflection point. Traditional preclinical models are no longer sufficient to predict human risk, costing biopharma millions in late-stage attrition and stalled pipelines. In 2026, toxicology enters a new era. The FDA's landmark 2025 roadmap to reduce reliance on animal testing has accelerated adoption of New Approach Methodologies (NAMs), including in vitro, microphysiological, and computational models. At the same time, CROs and technology developers are rapidly releasing new platforms, but uncertainty remains around predictivity, validation standards, and regulatory positioning. This meeting is the only industry-led forum dedicated to benchmarking what truly works in predictive toxicology. Designed by toxicologists for toxicologists, it brings together pharma, biotech, regulators, and model developers to critically evaluate in vivo, in vitro, and in silico strategies, share real IND case studies, and define fit-for-purpose model selection across modalities. If you are responsible for de-risking first-in-human decisions, advancing NAM adoption, or improving safety translation, this is the essential forum to separate innovation from hype and build toxicology strategies that stand up clinically and regulatorily. URLs:Tickets: https://go.evvnt.com/3457397-2?pid=5569Brochure: https://go.evvnt.com/3457397-3?pid=5569 Date and Time: Tuesday, 12 May 2026 at 08:00 - Thursday, 14 May 2026 at 17:00 Venue details: The Colonnade Hotel, 120 Huntington Avenue, Boston, Massachusetts, 02116, United States Category: Conferences | Science, Health and Medicine | Pharmaceuticals Prices:Drug Developer Pricing - Conference + Workshop Day: USD 3697.00,Drug Developer Pricing - Conference Only: USD 2699.00,Academic Pricing - Conference + Workshop Day: USD 2997.00,Academic Pricing - Conference Only: USD 2299.00,Service Provider Pricing - Conference + Workshop Day: USD 5297.00,Service Provider Pricing - Conference Only: USD 3799.00 Speakers: Wei Liang, Senior Scientist, Computational Toxicology, Abbvie, Ronnie Yeager, Research Fellow, Emerging Therapeutic Platforms (Development Sciences), Abbvie, Frank Teets, Head, Computational Biology, AI Proteins, Prathap Mahalingaiah, Senior Director, AstraZeneca, Shimeng Liu, Senior Scientist, AstraZeneca, John Kwon, Associate Director, AstraZeneca, David Rouquie, LifeHub Sophia Lead and Head, Toxicology Data Science, Bayer, Colin Choi, Associate Scientific Director, Biogen, Natalie Ketter, Global Head, Early Safety Sciences, Boehringer Ingelheim, Raghu Tadagavadi, Executive Director, Nonclinical Development and Safety, Century Therapeutics, Jacquelynn Lucas, Senior Director, Toxicology, Crescent Biopharma, Marc DeCristofaro, Director, Medicinal Safety, Daiichi Sankyo, Jorg Blumel, Senior Vice President and Head of Development Sciences, Genentech, Jutta Deckert, VP, R and D, Iksuda Therapeutics, Karolina Kopanska, Computational Toxicologist, John Hopkins University, Mathew Martin, Executive Director, Global Head, Computational Safety Sciences, Pfizer, Anna Kopec, Director, Investigative Toxicology, Pfizer, Pengyu Huang, Director and Head, In Vivo Pharmacology, Simcere Pharmaceutical Group, May Freag, Senior Scientist, Nonclinical Safety and Pharmacology (NCSP), Takeda Pharmaceutical, Takafumi Takai, Scientific Associate Director, Takeda Pharmaceutical